Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Health Sci J ; 49(3): 438-444, 2023.
Article in English | MEDLINE | ID: mdl-38314218

ABSTRACT

INTRODUCTION: The management of refractory obstructive hydrocephalus is a paramount neurosurgical challenge. The endoscopic third ventriculostomy (ETV) has been accepted as the procedure of choice for obstructive hydrocephalus, depending on the presence of certain risk factors, such as intracranial infections, young age, previous shunt failure and distorted anatomy of the ventricular floor, that predispose occlusion or obstruction of the CSF outflow through the stoma. CASE REPORT: A 20-year-old man with obstructive hydrocephalus due to primary aqueductal stenosis performed several neurosurgical procedures, including two previous ETV, without long term resolution. We performed another ETV, with stent placement at the stoma to prevent occlusion. After 25 months of asymptomatic follow-up, the patient presented with an enlarged fourth ventricle, and a new neuroendoscopic procedure showed a patent stoma and a well-placed stent. DISCUSSION: Stent placement on the third ventricular floor was already reported 19 times in the literature. Its success rate is about 94,7%, and complications happened in 2 cases, with functional impaired in only one of them. CONCLUSION: Third ventriculostomy with floor stenting proved to be an effective procedure in our case of complex hydrocephalus. It is a viable option in cases where there is a greater chance of stoma occlusion.

2.
Health Care Women Int ; 36(10): 1072-80, 2015.
Article in English | MEDLINE | ID: mdl-25187102

ABSTRACT

Multiple sclerosis (MS) is a chronic, neurological, immune-mediated disease that can worsen in the postpartum period. There is no consensus on the use of immunoglobulin for prevention of disease relapses after delivery. We have shown that the controversial beneficial effect of immunoglobulin given immediately after birth could not be observed in patients with MS.


Subject(s)
Immunoglobulins, Intravenous/therapeutic use , Mothers , Multiple Sclerosis, Relapsing-Remitting/prevention & control , Multiple Sclerosis/drug therapy , Postpartum Period/drug effects , Adult , Case-Control Studies , Female , Humans , Immunoglobulins, Intravenous/pharmacology , Multiple Sclerosis/complications , Multiple Sclerosis/physiopathology , Pregnancy , Pregnancy Complications/drug therapy , Pregnancy Complications/immunology , Pregnancy Outcome , Puerperal Disorders/prevention & control , Recurrence , Retrospective Studies , Risk Assessment , Risk Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...